

List of approved Form-IV intimation regarding discontinuation of scheduled formulations for the Financial Year 2023-2024 (As on 31.03.2024)

Sl.	Company Name	Date of application	Brand name	Composition	Reason for discontinuation	Date of final direction given to company by NPPA	To continue production / import and sale up to	Public Notice Issuance date
1	M/s Cipla Health Ltd., Mumbai	09.02.2023	CIPLADINE 10 % Ointment 10gm	Povidone Iodine IP....10%w/w	Insignificant market share and low sales	03.04.2023	31.07.2023	07.01.2023
2	Johnson and Johnson	21.03.2023	GASTRACTIV Tablets (Brand specific)		Declining Demand	31.05.2023	30.09.2023	03.08.2023
3	M/s Neon Laboratories Limited, Mumbai	03.08.2023	OXANA (NEON) PREFILLED SYRINGE 3 ML	Hydroxy Propyl Methyl Cellulose (2% W/V) PFS	Non viability	29.09.2023	01.02.2024	29.07.2023
4	M/s Alembic Pharmaceuticals Limited, Delhi	01.11.2023	Dubatran 110mg CAPSULE	Dabigatran Etexilate Mesilate 110mg Capsule	Low market demand	08.01.2024	01.05.2024	31.10.2023
5	M/s Mankind Pharma Ltd., Mumbai	25-12-2023	Pizofast 2.25G Injection (Brand specific)		Low sales	14.02.2024	31.06.2024	03.09.2023
6	M/s Mankind Pharma Ltd., Mumbai	25-12-2023	Pizofast 4.5G Injection (Brand specific)		Low sales	14.02.2024	31.06.2024	03.09.2023

7	M/s Mankind Pharma Ltd., Mumbai	25-12-2023	Iverkind- 6mg (Brand specific)		Low sales	14.02.2024	31.06.2024	03.09.2023
8	M/s Mankind Pharma Ltd., Mumbai	25-12-2023	Iverkind- 12mg (Brand specific)		Low sales	14.02.2024	31.06.2024	03.09.2023